Joshua Rychak Email

VP R&D, Gene Therapy . Poseida Therapeutics

Current Roles

Employees:
314
Revenue:
$46.3M
About
Poseida Therapeutics is translating best-in-class gene engineering technologies into lifesaving cell therapies. The company is developing CAR T-cell immunotherapies for multiple myeloma, prostate and other cancer types, as well as gene therapies for orphan diseases. P-BCMA-101 is Poseida's lead CAR-T therapy currently in Phase 1 clinical development for the treatment of multiple myeloma. Poseida has assembled a suite of industry-leading gene engineering technologies, including the piggyBac DNA Modification System, TAL-CLOVER and Cas-CLOVER site-specific nucleases, and Footprint-Free Gene Editing (FFGE). For more information, visit www.poseida.com.
Poseida Therapeutics Address
9390 Towne Centre Drive
San Diego, CA
United States
Poseida Therapeutics Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.